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Abstract  
Background: The benefit of statins on stroke incidence is well known. However, data on the 
relationship between pre and post stroke statin use, recurrence and survival outcomes are 
limited. We aim to investigate the short-term and long-term relationship between statin 
prescription, stroke recurrence and survival in patients with first-ever ischemic stroke.  
Methods: Data were collected from the population-based South London Stroke Register for 
the years 1995-2015. Patients were assessed at time of first ever stroke, three months and 
annually thereafter. Data on vascular risk factors, treatments prescribed, socio-demographic 
characteristics, stroke subtype, survival and stroke recurrence were collected. Cox 
proportional hazard analyses were used to assess the relationship of statin prescriptions pre- 
and post-stroke on stroke severity, and long-term recurrence and survival.   
Results: Patients prescribed statins both pre- and post-stroke showed a 24% reduction in 
mortality (adjusted Hazard Ratio aHR=0.76, 0.60-0.97), those who were prescribed statins 
pre-stroke and then stopped post stroke showed greater risk of mortality (aHR=1.85, 1.10-
3.12) and stroke recurrence (aHR=3.25, 1.35-7.84) compared to those that were not 
prescribed statins at any time. No associations were observed between pre-stroke statin and 
severity of the initial stroke overall, though a protective effect against moderate/severe stroke 
(Glasgow Coma Scale≤12) was observed in those aged 75y+ (aOR=0.70, 0.52-0.95) 
Conclusions: Statins play a significant role in improving survival rates after a stroke. 
Adherence to the National Guidelines that promote statin treatment primary and secondary 
prevention of stroke should be monitored and a focus for quality improvement programs.  
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Background and purpose 
The association between total cholesterol levels and ischemic stroke risk is well 
established[1-4]. Decreasing LDL-Cholesterol levels is associated with significant reductions 
in stroke/TIA incidence [5-9] and low HDL-Cholesterol is associated with higher risk of 
ischemic stroke/TIA [1,4,10,11]. Statins reduce low-density lipoprotein cholesterol (LDL-C) 
levels[12] and have been shown to increase HDL-C levels and functioning[13]. Their ability 
to reduce stroke incidence is well known [7,14-17] but the evidence on the effect of statin use 
on stroke severity is mixed; some finding a reduction in stroke severity[18,19] but others 
finding no impact[20]. A systematic review of observational studies report an improved 
functional outcome at 90 days in those already on statins but this is not maintained to one 
year[21].  
There is only one prospective randomised trial of statins after stroke and this provides 
evidence of a benefit in statin use for stroke recurrence and other cardiovascular events but 
no impact on overall mortality[22]. Observational studies have provided some evidence that 
statin use is associated with a reduction in both recurrence and mortality after stroke[23,24] 
and a detrimental impact of statin withdrawal after stroke[23,25]  
In randomized control trials, pre-intervention treatment and long-term effect of statins are not 
well investigated due to the lack of long-term studies and insufficient patient medication 
history. In the present study, we aim to investigate the relationship between pre-stroke statin 
use on stroke severity and both pre- and post-stroke statin use on two major outcomes after 
acute ischaemic stroke in patients registered on the South London Stroke Register (SLSR): 
stroke recurrence and survival.  
 
  
4 
 
Methods 
Data for the present study were obtained from the South London Stroke Register (SLSR), a 
prospective population-based stroke register of first strokes recorded in an inner area of South 
London comprising 22 electoral wards in Southwark and Lambeth. This study includes 
individuals diagnosed with their first stroke between January 1995 and December 2015.  
Follow-up data were collected prospectively by specially trained field workers and nurses at 
three months after the patient’s first stroke and annually thereafter via validated postal or 
face-to-face interviews with patients and/or their carers. A capture-recapture analysis was 
undertaken to establish completeness of stroke incidence data and estimates that the register 
coverage is 88%[26]. Details of the stroke register methodology have been published 
elsewhere,[27] a short summary of key elements for this analysis is provided here. 
All first strokes according to the World Health Organisation definition of stroke were 
included (fatal and non-fatal). Diagnosis was verified by a medical doctor. Neuroradiology 
reports, cerebrospinal fluid analysis and necropsy findings were used to classify strokes into 
ischemic stroke, primary intracerebral haemorrhage or subarachnoid haemorrhage.  
Vascular risk factors for stroke were either self-reported or extracted from medical notes. 
These included transient ischaemic attack, atrial fibrillation, ischemic heart disease (history 
of angina or myocardial infarction), hypertension, diabetes mellitus, hypercholesterolemia 
and smoking status. Pre-morbid disability was measured using Barthel Index scores. A cut-
off of 15 was used to classify patients by mild disability/independent, disabled or unknown.  
Severity of the initial stroke was assessed using Glasgow Coma Scores (lower and higher 
than 13), urinary incontinence, dysphagia (failure of swallow test) and motor deficits.  
At each follow-up details including date of new strokes were recorded. In addition, all strokes 
occurring within the SLSR area were reported to the register including recurrent strokes. The 
definition of stroke recurrence was by the same WHO criteria, only recurrences that had 
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taken place more than 21 days post-stroke or in a different vascular area were counted. Death 
was confirmed by the Office for National Statistics. Information on death and recurrence is 
assumed to be complete for all individuals.  
Medication prior to the initial stroke and at discharge were recorded as free text reported by 
the individual and from clinic notes, prescriptions at three months were by self-report. 
Medications were grouped by indication using the British National Formulary coding. It is 
assumed that if a medication is not recorded but the interview was conducted then it was not 
prescribed. 
The impact of pre-stroke medications and medications given within the first three months 
(including at discharge) are investigated.  
Statistical methods 
Socio-demographic characteristics, stroke subtype, pre-stroke vascular risk factors, disability 
status and living conditions of the study population were described. The proportion of 
patients on different pre-stroke medication (cholesterol-lowering, antihypertensive, 
antithrombotic) were calculated. Associations between pre-stroke statin use and initial stroke 
severity were assessed using Poisson regression adjusting for demographic factors (age, sex, 
ethnicity, socio-economic status), pre-stroke vascular risk factors (TIA, atrial fibrillation, 
ischemic heart disease, smoking, hypertension, diabetes), other pre-stroke medications 
(antihypertensive, antiplatelet, anticoagulant) and year of stroke. Subgroup analyses were 
conducted for those under 55yrs at time of first stroke, in the elderly (75+yrs) and in those 
who had a diagnosis of atrial fibrillation prior to stroke. Due to changes in recording of prior 
diagnosis of ischaemic heart disease over the course of the register this is calculated as a 
combination of previous MI, angina or ischaemic heart disease. 
Event rates for death and recurrence were calculated for: 
1. Patients who have never been treated with a statin (our baseline for comparison) 
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2. Patients who have had statin treatment prior to their stroke but have discontinued 
treatment since. 
3. Patients who have only had statin treatment after their stroke (within first 3 months) 
4. Patients who have been treated with a statin before and after their stroke 
Patients were excluded from the analysis comparing pre- and post-stroke statin use if they 
died before discharge, did not have discharge information or did not have a three-month 
follow-up interview. The relationship between these different groups and long-term survival 
and recurrence was first determined on a univariate level using Cox proportional hazards 
model. This same model was used in a multivariate analysis, where we adjusted for potential 
confounding factors. Year of first stroke is grouped into 5-year bands. An interaction between 
statin effects and year of first stroke is assessed in the fully adjusted model using a likelihood 
ratio test. 
Analyses were not adjusted for pre-stroke hypercholesterolemia as it is highly correlated with 
statin use. 
 
Results 
A total of 3,803 individuals were diagnosed with an ischaemic stroke between 1st January 
1995 and 31st December 2015 and registered on the SLSR. The study population consisted of 
1,923 (51%) males, 1,690 (45%) were over 75 years with only 171 (5%) under 45 and 1061 
(27%) of non-white ethnicity. The majority (2,432, 64%) had a previous diagnosis of 
hypertension, further details are provided in table 1. 
Prior to their first stroke 2,009 (53%) of individuals were on antihypertensive medication, 
only around a fifth (742, 20%) were on cholesterol lowering medication (738, 99% of these 
were statin) (table 2). 
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Of the 2,006 that had both discharge and three month information 1,015 (51%) individuals 
were prescribed cholesterol lowering medication (1000, 99% of these were statin) within the 
first three months of their initial stroke. This has increased from 7% in 1995-1999 to 87% in 
2010-2015. Overall, this resulted in 967 (48%) having never received statin treatment, 372 
(19%) having a statin both pre- and post- their initial stroke and 1,039 (52%) at some point.  
After accounting for demographic differences, pre-stroke vascular risk factors and other 
medications there was no association between having a prescription for a statin prior to the 
initial stroke and any stroke severity outcome (table 3). In subgroup analyses of the 
participants by age group statin use showed a statistically significant protective effect against 
stroke severity measured by the GCS in those aged 75y+ (OR=0.70, 0.52-0.95) a similar 
effect size was observed in the <55yr age group but this was not statistically significant 
(OR=0.70, 0.29-1.69). We saw no associations within either age group between statin use and 
other severity measures. We analysed the subgroup of patients with a diagnosis of AF and 
found similar results to those in table 3 with no association between pre-stroke statin use and 
stroke severity in this subgroup (supplementary table 1). 
 
There were 1,173 deaths in 12,763 person years giving a mortality rate of 91.9/1000pys (95% 
confidence interval 86.8 – 97.3). The maximum follow-up time was 19.6 years with median 
5.0 years. Those included in the analysis were more likely to be economically active, have 
previous hypercholesterolemia or TIA and have a more severe stroke by Glasgow coma scale 
compared to those who did not have both pieces of data but had not died before discharge, we 
adjust for these in the analysis. 
 
In a cox proportional hazards model (table 4) statin use pre-stroke had no impact on risk of 
death. A statin prescription only after stroke shows a 31% reduction in mortality compared to 
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never using a statin (aHR=0.69, 0.57 – 0.83). Having a statin both before and after the stroke 
reduces mortality by 24% (aHR=0.76, 0.60-0.97). However, statin use before stroke that is 
then stopped results in an increased risk of dying compared to never having a statin 
prescription (aHR=1.85, 1.10-3.12). Survival curves by statin prescription are presented in 
figure 1a. 
 
255 individuals had at least one recurrence in 11,668 person years of time giving a recurrence 
rate of 21.9/1000pys (95% confidence interval 19.3 – 24.7). The maximum follow-up time 
was 19.6 years with median 4.4 years. 
No benefit of statin use was found on the incidence of recurrence after adjustment for 
baseline risk factors, demographics and prescription of other medications (table 4). However, 
there is a suggestion that risk of recurrence is decreased in those that were prescribed statins 
at discharge compared to never having a statin prescription (adjusted hazard ratio=0.66, 95% 
confidence interval 0.43 – 1.01). As with survival there is evidence that having a statin 
prescribed prior to the stroke which is then stopped is detrimental resulting in increased risk 
of a stroke recurrence (aHR=3.25, 95% CI 1.35 – 7.84). However, this is based on very few 
events. 
There was no interaction between year of first stroke and effect of pre- and post-stroke statin 
use on recurrence (p-value=0.891) or survival (p-value=0.159).  
 
Discussion 
We have demonstrated that statin use prior to a stroke is not associated with a reduction in the 
severity of the resulting neurological deficit in the overall population, although our subgroup 
analysis did find a significant protective effect in those 75+years old. It is possible that the 
reason we failed to detect a significant overall effect is because we used the GCS to measure 
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the degree of stroke severity. Studies reporting reduction of the neurological deficits in the 
statin group have used the NIHSS score, a more sensitive tool. However, the reported 
differences in median NIHSS between groups in these studies is around 1 point[28-30]. This 
suggest that the protective effect of pre-stroke statins may be clinically insignificant for 
younger patients, and only clinically relevant for elderly ones. 
 
Statins prescribed in the first few months after a stroke are associated with a reduction in 
mortality. This agrees with other observational studies that have found a similar mortality 
reduction with post-stroke statin use[23,24,29-32]. Although improved survival associated 
with statin use was not seen on a previous prospective randomised trial[22], the authors 
acknowledged that the study was not powered enough to assess reduction in all-cause 
mortality.The trial did show a beneficial impact of statin use on recurrence, which is 
supported by the observational studies. This decrease in recurrence is not shown in our data 
where the impact of statin prescription at discharge does not quite reach statistical 
significance. However, it is likely this is due to the distribution of stroke aetiological subtypes 
in our population, where only 9.3% of strokes where due to large artery atherothrombosis, 
while 27.8% were cardioembolic and 24.2% were undetermined[33]. 
Statin use pre-stroke which is then discontinued is associated with an increased risk of both 
recurrence and mortality, a finding supported by other studies[23,25,34]. It is difficult to 
disentangle cause and effect in this scenario, those that were on statins prior to their stroke 
may have been more unwell and therefore at higher risk of a poor outcome anyway. 
However, pre-stroke statin use was not associated with outcomes in our data. It may also be 
that the decision to stop statins is taken as part of the end of life pathway.  
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We have adjusted for conditions prior to the stroke; atrial fibrillation, diabetes, hypertension, 
TIA and ischaemic heart disease but there may be others. In future studies it would be 
beneficial to look at the impact of comorbidities in this group. 
 
As this is an observational study it is not possible to account for all possible confounding 
factors and so we can only infer associations rather than any causative effect of statin use. 
Medication prescriptions are taken from self-report or medical notes however this is only an 
indication of prescription, not necessarily usage, additionally dose is not recorded. The 
impact of any medications on outcomes may be diluted through non-adherence to treatment 
or differing prescriptions. We expect to have complete data for the recurrence and survival 
outcomes. In addition to patient reports recurrences are monitored through the register which 
uses several sources to identify strokes within the register area. The only loss of information 
may be if individuals move out of the area but these are still followed-up in annual interviews 
and so will be kept to a minimum. Death reports are linked through the Office for National 
Statistics and are therefore complete. 
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